Novo Nordisk Offering Large Discount on Wegovy in Bid to Recapture Market
It’s been a tough year for Novo Nordisk, the Danish pharmaceutical company behind the GLP-1 drugs Ozempic and Wegovy. Competitors are nipping at its heels, cheaper knockoffs have been eating into its sales, and it just gave the boot to its former CEO. Now, hoping its worst days are behind it, Novo says it’s offering […]
GLP-1 Microdosing Trends and Risks
WSJ article discusses the growing trend of microdosing GLP-1 medications, like Ozempic and Zepbound, which are primarily used for weight loss and diabetes management. Some individuals are taking smaller or less frequent doses than prescribed, often motivated by cost savings, a desire to reduce side effects, or the belief in potential health benefits beyond weight loss. While some doctors […]
Patients navigate an ‘absolutely insane’ maze to afford weight-loss drugs
Health insurance plans are changing how they cover GLP-1 drugs for weight loss to rein in costs, forcing doctors and patients to adapt on the fly.
There’s No Such Thing as a Natural Ozempic Diet. Still, Following These Tips Can Help
The popularity of semaglutide, the active ingredient in Ozempic, has led many people to seek alternatives that can replicate its effects without a trip to the pharmacy. Like any other drug, Ozempic and similar medications come with side effects, a high cost, and the requirement of a doctor’s prescription. As a result, the idea of […]
Popular Off-Brand Ozempic Products, Used for Weight-Loss, Could Get Harder to Find
The weight-loss industry is a huge one in the U.S. Numbers say it all, and the global weight management market size was valued at $142.58 billion in 2022 and is projected to grow at a compound annual growth rate of 9.94% from 2023 to 2030, according to Grand View Research. According to the Market Research […]
Why Some People Are Microdosing Popular Weight-Loss Drugs
Some consumers take tiny doses of Ozempic and other GLP-1 drugs or stretch out doses to cut costs and side effects Microdosing isn’t just popular for psychedelics. Some consumers are taking smaller than standard doses of GLP-1s—the popular class of weight-loss and diabetes drugs that include Ozempic, …